Merck (MRK) Cash from Discontinued Operations (2020 - 2021)

Merck (MRK) posted quarterly Cash from Discontinued Operations of 702000000.0 for Q4 2021, down 236.31% YoY from 515000000.0 in Q4 2020, and down 210.03% sequentially from 638000000.0 in Q3 2021.

Merck (MRK) Cash from Discontinued Operations (2020 - 2021) Analysis & Trends

Merck has disclosed Cash from Discontinued Operations across 2 years of filings, most recently posting 702000000.0 for Q4 2021.

  • In Q4 2021, Cash from Discontinued Operations fell 236.31% year-over-year to 702000000.0; the TTM figure through Sep 2022 stood at 702000000.0 (down 144.83% YoY), while the FY2021 annual figure was 349000000.0, down 85.37% from the prior year.
  • Cash from Discontinued Operations retreated to 702000000.0 in Q4 2021, from 638000000.0 in the prior quarter.
  • Over the last five years, Cash from Discontinued Operations for MRK reached as high as 638000000.0 in Q3 2021 and fell as low as 702000000.0 in Q4 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn -
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 3.36 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2021 -702.00 Mn
Dec 31, 2021 -702.00 Mn
Sep 30, 2021 638.00 Mn
Sep 30, 2021 638.00 Mn
Jun 30, 2021 -86.00 Mn
Jun 30, 2021 -86.00 Mn
Mar 31, 2021 499.00 Mn
Mar 31, 2021 499.00 Mn
Dec 31, 2020 515.00 Mn
Dec 31, 2020 515.00 Mn
Sep 30, 2020 522.00 Mn
Sep 30, 2020 522.00 Mn